(Testosterone Enanthate 200mg /Testosterone Propionate 50mg mL/ 10mL Vial)
Compound is used to treat hormone disorders caused by testosterone deficiency, androgenic deficit after castrating, eunuchoidism, impotence hormonal origin, signs of male climax (decreased libido and physical and intellectual activity) in acromegaly, in early-stage prostate hypertrophy, osteoporosis caused by androgenic insufficiency.
Testosterone Enanthate and Testosterone propionate is used primarily in androgen replacement therapy. It is the most widely used form of testosterone in androgen replacement therapy. The medication is specifically approved, in the United States, for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. It is also used in masculinizing hormone therapy for transgender men.
Testosterone propionate a relatively short elimination half-life and mean residence time of 0.8 days and 1.5 days, respectively. As such, it has a short duration of action and must be administered two to three times per week.
Testosterone enanthate has an elimination half-life of 4.5 days and a mean residence time of 8.5 days when used as a depot intramuscular injection. It requires frequent administration of approximately once per week, and large fluctuations in testosterone levels result with it, with levels initially being elevated and supra physiological.
Dosage and duration of therapy with Testosterone Enanthate 200mg /Propionate 50mg injection will depend on age, sex, diagnosis, patient’s response to treatment, and appearance of adverse effects. Care should be taken to slowly inject the preparation deeply into the gluteal muscle, being sure to follow the usual precautions for intramuscular administration, such as the avoidance of intravascular injection (see PRECAUTIONS).
In general, total doses above 400 mg per month are not required because of the prolonged action of the preparation. Injections more frequently than every two weeks are rarely indicated.
NOTE: Use of a wet needle or wet syringe may cause the solution to become cloudy; however this does not affect the potency of the material. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Testosterone Enanthate/Propionate mix injection is a clear, colorless to pale yellow solution.
Male hypogonadism: As replacement therapy, i.e., for eunuchism, the suggested dosage is 50 to 400 mg every 2 to 4 weeks.
In males with delayed puberty: Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose. Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months. X-rays should be taken at appropriate intervals to determine the amount of bone maturation and skeletal development.
Palliation of inoperable mammary cancer in women: A dosage of 200 to 400 mg every 2 to 4 weeks is recommended. Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease.
